- Home
- PSFE vs IMRX Comparison
PSFE vs IMRX Comparison
Compare PSFE & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSFE | IMRX |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United Kingdom | United States |
| Employees | 3300 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.1M | 322.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSFE | IMRX |
|---|---|---|
| Price | $7.38 | $4.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $10.60 | ★ $17.20 |
| AVG Volume (30 Days) | 468.7K | ★ 725.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.95 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.95 | $1.10 |
| 52 Week High | $18.15 | $10.08 |
Technical Indicators
Market Signals| Indicator | PSFE | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 46.67 |
| Support Level | $6.58 | $4.49 |
| Resistance Level | $7.39 | $5.24 |
| Average True Range (ATR) | 0.43 | 0.25 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 80.75 | 25.60 |
Price Performance
Historical ComparisonAbout PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.